OOIR: Observatory of International Research

Papers

(The H4-Index of Microbial Cell Factories is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Microbial lipases and their industrial applications: a comprehensive review	369
Postbiotics-parabiotics: the new horizons in microbial biotherapy and functional foods	281
Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health	193
Bacillus subtilis: a universal cell factory for industry, agriculture, biomaterials and medicine	186
Current developments on polyhydroxyalkanoates synthesis by using halophiles as a promising cell factory	130
A critical review on various feedstocks as sustainable substrates for biosurfactants production: a way towards cleaner production	124
Rhamnolipid the Glycolipid Biosurfactant: Emerging trends and promising strategies in the field of biotechnology and biomedicine	120
Functional expression of polyethylene terephthalate-degrading enzyme (PETase) in green microalgae	91
Challenging microalgal vitamins for human health	85
Application of different types of CRISPR/Cas-based systems in bacteria	85
Pediococcus pentosaceus, a future additive or probiotic candidate	81
Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation	79
Anti-cancer and anti-inflammatory effects elicited by short chain fatty acids produced by Escherichia coli isolated from healthy human gut microbiota	76
Production and characterization of surfactin-like biosurfactant produced by novel strain Bacillus nealsonii S2MT and it's potential for oil contaminated soil remediation	75
Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children	68
Engineering probiotics as living diagnostics and therapeutics for improving human health	66
Emerging prospects of macro- and microalgae as prebiotic	64
Maximizing PHB content in Synechocystis sp. PCC 6803: a new metabolic engineering strategy based on the regulator PirC	61
De novo resveratrol production through modular engineering of an Escherichia coli–Saccharomyces cerevisiae co-culture	61
Enhanced production of taxadiene in Saccharomyces cerevisiae	55
The history, state of the art and future prospects for oleaginous yeast research	55
Microbial glycoconjugates in organic pollutant bioremediation: recent advances and applications	52
Microbial production of ectoine and hydroxyectoine as high-value chemicals	50
Customized yeast cell factories for biopharmaceuticals: from cell engineering to process scale up	49
Multi-pathogen infections and Alzheimer’s disease	49

Gold standard for nutrition: a review of human milk oligosaccharide and its effects on infant gut microbiota	48
Gut microbial dysbiosis in individuals with Sjögren’s syndrome	47
Biosynthesis of aromatic polyketides in microorganisms using type II polyketide synthases	45
Extracellular vesicles and pasteurized cells derived from Akkermansia muciniphila protect against high-fat induced obesity in mice	41
Biosurfactant from vaginal Lactobacillus crispatus BC1 as a promising agent to interfere with Candida adhesion	39
TAK-242 ameliorates DSS-induced colitis by regulating the gut microbiota and the JAK2/STAT3 signaling pathway	38
Engineering the Calvin–Benson–Bassham cycle and hydrogen utilization pathway of Ralstonia eutropha for improved autotrophic growth and polyhydroxybutyrate production	38
Sexual dimorphism of gut microbiota at different pubertal status	38
Engineered microbial consortia: strategies and applications	37
Biovalorisation of crude glycerol and xylose into xylitol by oleaginous yeast Yarrowia lipolytica	37
Impact of organic carbon acquisition on growth and functional biomolecule production in diatoms	36
Gut microbial characteristics of adult patients with allergy rhinitis	36